However, the contraditory effects of PPARβ/δ agonists on HSCs proliferation and liver fibrosis hindered PPARβ/δ agonists from entering clinical trials234–236, which might be due to discrepancies in the ligands, dosage, and in vivo pharmacological properties of compounds. This evidence concerns the gene PPARD and Hepatic fibrosis.